Solid Biosciences (SLDB) Competitors $5.92 +0.26 (+4.54%) Closing price 03:59 PM EasternExtended Trading$5.92 +0.00 (+0.05%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock SLDB vs. ANIP, ARQT, VCEL, DYN, BEAM, APGE, TWST, IMCR, TVTX, and AUPHShould you be buying Solid Biosciences stock or one of its competitors? The main competitors of Solid Biosciences include ANI Pharmaceuticals (ANIP), Arcutis Biotherapeutics (ARQT), Vericel (VCEL), Dyne Therapeutics (DYN), Beam Therapeutics (BEAM), Apogee Therapeutics (APGE), Twist Bioscience (TWST), Immunocore (IMCR), Travere Therapeutics (TVTX), and Aurinia Pharmaceuticals (AUPH). These companies are all part of the "pharmaceutical products" industry. Solid Biosciences vs. Its Competitors ANI Pharmaceuticals Arcutis Biotherapeutics Vericel Dyne Therapeutics Beam Therapeutics Apogee Therapeutics Twist Bioscience Immunocore Travere Therapeutics Aurinia Pharmaceuticals ANI Pharmaceuticals (NASDAQ:ANIP) and Solid Biosciences (NASDAQ:SLDB) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, analyst recommendations, profitability, valuation, institutional ownership, dividends, risk and earnings. Which has stronger valuation and earnings, ANIP or SLDB? ANI Pharmaceuticals has higher revenue and earnings than Solid Biosciences. ANI Pharmaceuticals is trading at a lower price-to-earnings ratio than Solid Biosciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioANI Pharmaceuticals$614.38M3.22-$18.52M-$0.77-118.38Solid BiosciencesN/AN/A-$124.70M-$2.80-2.11 Do analysts recommend ANIP or SLDB? ANI Pharmaceuticals currently has a consensus target price of $84.75, suggesting a potential downside of 7.02%. Solid Biosciences has a consensus target price of $15.00, suggesting a potential upside of 153.51%. Given Solid Biosciences' stronger consensus rating and higher probable upside, analysts clearly believe Solid Biosciences is more favorable than ANI Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ANI Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 3.00Solid Biosciences 0 Sell rating(s) 0 Hold rating(s) 10 Buy rating(s) 2 Strong Buy rating(s) 3.17 Which has more risk and volatility, ANIP or SLDB? ANI Pharmaceuticals has a beta of 0.61, suggesting that its stock price is 39% less volatile than the S&P 500. Comparatively, Solid Biosciences has a beta of 2.44, suggesting that its stock price is 144% more volatile than the S&P 500. Is ANIP or SLDB more profitable? Solid Biosciences has a net margin of 0.00% compared to ANI Pharmaceuticals' net margin of -1.37%. ANI Pharmaceuticals' return on equity of 25.03% beat Solid Biosciences' return on equity.Company Net Margins Return on Equity Return on Assets ANI Pharmaceuticals-1.37% 25.03% 8.00% Solid Biosciences N/A -69.70%-56.74% Do institutionals & insiders hold more shares of ANIP or SLDB? 76.1% of ANI Pharmaceuticals shares are owned by institutional investors. Comparatively, 81.5% of Solid Biosciences shares are owned by institutional investors. 11.1% of ANI Pharmaceuticals shares are owned by insiders. Comparatively, 1.9% of Solid Biosciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. Does the media refer more to ANIP or SLDB? In the previous week, ANI Pharmaceuticals had 9 more articles in the media than Solid Biosciences. MarketBeat recorded 35 mentions for ANI Pharmaceuticals and 26 mentions for Solid Biosciences. Solid Biosciences' average media sentiment score of 0.64 beat ANI Pharmaceuticals' score of 0.26 indicating that Solid Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ANI Pharmaceuticals 17 Very Positive mention(s) 2 Positive mention(s) 7 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Solid Biosciences 6 Very Positive mention(s) 3 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive SummarySolid Biosciences beats ANI Pharmaceuticals on 9 of the 16 factors compared between the two stocks. Get Solid Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for SLDB and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding SLDB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SLDB vs. The Competition Export to ExcelMetricSolid BiosciencesMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$460.75M$3.09B$5.83B$9.73BDividend YieldN/A2.23%3.84%4.09%P/E Ratio-2.1121.1631.1625.99Price / SalesN/A396.94474.86122.97Price / CashN/A43.0937.1558.38Price / Book1.788.069.116.38Net Income-$124.70M-$54.72M$3.26B$265.56M7 Day Performance-3.16%2.52%2.06%1.89%1 Month Performance-5.02%7.54%5.08%1.23%1 Year Performance-37.32%13.01%31.26%21.10% Solid Biosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SLDBSolid Biosciences3.5725 of 5 stars$5.92+4.5%$15.00+153.5%-43.1%$460.75MN/A-2.11100ANIPANI Pharmaceuticals3.1466 of 5 stars$88.78+0.0%$84.75-4.5%+48.6%$1.92B$614.38M-115.00600Insider TradeARQTArcutis Biotherapeutics1.8832 of 5 stars$15.71+0.5%$19.80+26.0%+89.3%$1.89B$263.47M-20.98150Positive NewsVCELVericel2.554 of 5 stars$35.88-5.4%$60.33+68.2%-26.3%$1.81B$237.22M298.97300Positive NewsDYNDyne Therapeutics3.2983 of 5 stars$12.32+0.7%$33.80+174.3%-74.0%$1.76BN/A-3.20100BEAMBeam Therapeutics2.0818 of 5 stars$17.23-1.7%$48.45+181.3%-37.2%$1.75B$63.52M-3.84510APGEApogee Therapeutics3.5165 of 5 stars$37.86+1.3%$99.00+161.5%-24.8%$1.74BN/A-9.1291TWSTTwist Bioscience4.1868 of 5 stars$28.39-0.9%$49.40+74.0%-40.0%$1.72B$312.97M-19.61990Positive NewsIMCRImmunocore1.851 of 5 stars$32.68-1.0%$58.00+77.5%-10.6%$1.64B$356.15M-81.61320Positive NewsTVTXTravere Therapeutics2.4499 of 5 stars$18.30+1.4%$32.21+76.0%+104.7%$1.63B$333.87M-8.98460AUPHAurinia Pharmaceuticals2.7024 of 5 stars$12.16+1.2%$12.00-1.3%+83.3%$1.60B$235.13M28.27300Positive News Related Companies and Tools Related Companies ANI Pharmaceuticals Competitors Arcutis Biotherapeutics Competitors Vericel Competitors Dyne Therapeutics Competitors Beam Therapeutics Competitors Apogee Therapeutics Competitors Twist Bioscience Competitors Immunocore Competitors Travere Therapeutics Competitors Aurinia Pharmaceuticals Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SLDB) was last updated on 8/22/2025 by MarketBeat.com Staff From Our PartnersEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredAltucher: It Looks Like My Trump prediction is coming trueNew Hampshire just launched a Strategic Crypto Reserve — and James Altucher says it’s the first sign that “Tru...Paradigm Press | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredThe Tiny Stock Set to Soar with Musk's AI AmbitionsThe Tiny Stock Set to Soar with Musk's AI Ambitions While Musk builds one of the most ambitious AI empires ...Behind the Markets | SponsoredWhen the levee breaksThe U.S. Treasury just confirmed it plans to borrow $1.01 trillion this quarter—nearly double what was project...Porter & Company | SponsoredMusk’s Project Colossus could mint millionairesI predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new milliona...Brownstone Research | SponsoredThink you missed gold’s boom? Think againIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Solid Biosciences Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Solid Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access